Johnson & Johnson/Janssen COVID-19 Vaccine and Cerebral Venous Sinus Thrombosis with Thrombocytopenia – Update for Clinicians on Early Detection and Treatment (COCA Call)

Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare

If you weren’t able to attend this April 15, 2021 COCA Call, you view the recording (57 minutes, 26 seconds) here as well as obtain the 61-slide handout.  I encourage you to listen to the recording and review the slides.  This is important information.  Facility staff, in particular, are expressing hesitancy to get any of the COVID-19 vaccines.  Overcoming such hesitancy requires us to be honest and provide information needed to understand the vaccines. 

“This COCA Call will present the latest evidence on cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated with the administration of the Johnson & Johnson/Janssen COVID-19 vaccine.  Speakers will discuss what is known about CVST, the importance of early detection, and updated vaccine recommendations.” 

If you didn’t see this blog posted April 16, 2021, please take a few minutes now to read it.  Included in this CDC and CMS update, you’ll find this statement: